Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2006

01-05-2006 | Original Article

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

Authors: Takuji Okusaka, Hiroshi Ishii, Akihiro Funakoshi, Kenji Yamao, Shinichi Ohkawa, Soh Saito, Hiroshi Saito, Toshio Tsuyuguchi

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2006

Login to get access

Abstract

Purpose: This phase II study was conducted to evaluate the efficacy and toxicity of single-agent gemcitabine in patients with advanced or metastatic biliary tract cancer. Patients and methods: Gemcitabine 1,000 mg/m2 was administered as an intravenous 30-min infusion on days 1, 8, and 15 for every 28 days. Results: Forty chemonaive patients with a median age of 61 (range 33–73) were enrolled, and all 40 patients were involved in efficacy and safety analyses. Seven (17.5%) achieved partial response; 15 (37.5%) had stable disease; 17 (42.5%) had progressive disease; and 1 (2.5%) was not evaluated. The median survival time was 7.6 months, and the 1-year survival rate was 25.0%. Grade 3/4 neutropenia occurred in 12 patients (30.0%), leukopenia in five patients (12.5%), and anemia in four patients (10.0%). The most common grade 3/4 nonhematologic toxicities were elevated ALT (15.0%) and elevated γ-GTP (12.5%). One patient had grade 4 hemolytic uremic syndrome and recovered after discontinuation of gemcitabine. Conclusions: In single-agent therapy, gemcitabine demonstrated moderate efficacy with manageable toxicity in patients with advanced or metastatic biliary tract cancer. Further evaluations are warranted, including the exact impact of gemcitabine on the management of advanced or metastatic biliary tract cancer.
Appendix
Available only for authorised users
Literature
1.
Aabo K, Pedersen H, Rorth M (1985) Cisplatin in the treatment of advanced gastric carcinoma: a phase II study. Cancer Treat Rep 69:449–450PubMed
2.
Agelaki S, Papakostas P, Stathopoulos G, Aravantinos G, Kalbakis K, Sarra E et al (1999) Phase II study of docetaxel with G-CSF support as first-line treatment for unresectable or advanced biliary tract carcinoma: a multicenter phase II trial. Proc Am Soc Clin Oncol 18:276a (Abstract No: 1058)
3.
Arroyo G, Gallardo J, Rubio B, Orlandi L, Yañez M, Gamargo C et al (2001) Gemcitabine (GEM) in advanced biliary tract cancer (ABTC). Experience from Chile and Argentina in phase II trials. Proc Am Soc Clin Oncol 20:157a (Abstract 626)
4.
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
5.
Chen JS, Lin YC, Jan YY, Liau CT (2001) Mitomysin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Durgs 12:339–343CrossRef
6.
Davis HL Jr, Ramirez G, Ansfield FJ (1974) Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193–197PubMedCrossRef
7.
Dobrila-Dintinjana R, Kovac D, Depolo A, Uravic M, Dintinjana M (2000) Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer. Am J Gastroenterol 95:2476
8.
Eng C, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT et al (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 276:565–569CrossRef
9.
Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F et al (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653–656CrossRefPubMed
10.
Ellis PA, Norman A, Hill A, O’Brien ME, Nicolson M, Hickish T et al (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors. Eur J Cancer 31A:1594–1598CrossRef
11.
Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965–969PubMedCrossRef
12.
Fishkin P, Alberts S, Mahoney M, Sargent D, Goldberg R, Burgart L et al (2001) Irinotecan in patients with advanced gallbladder carcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 20:155a (Abstract No: 618)
13.
Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023–2032PubMed
14.
Gebbia V, Giuliani F, Verderame F, Boerellino N, Mauceri G, Tirrito M, et al (2001) Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19:4089–4091PubMed
15.
Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM in carcinoma of the biliary tract. J Clin Oncol 2:1245–1248PubMed
16.
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2×,2×-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117PubMed
17.
Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG et al (2004) Gemcitabine-associated thrombotic microangiopathy. Cancer 100:2664–2670CrossRefPubMed
18.
Ikeda M, Okusaka T, Ueno H, Furuse J, Ishii H, Morizane C, et al (2004) Phase II study of UFT for advanced extra- and intrahepatic cholangiocarcinoma (in Japanese). J Jpn Biliary Assoc 18:421
19.
Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306–2310PubMed
20.
Kajanti M, Pyrhonen S (1994) Epribicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 17:223–226PubMedCrossRef
21.
Kubicka S, Tietze MK, Rudolph L, Manns MP (1999) Phase II study of gemcitabine in patients with nonresectable cancer of the biliary system. Eur J Cancer 35(suppl 4):S151 (Abstract 559)
22.
Kuroishi T, Hirose K, Tajima K, Tominaga S (1999) Prediction of cancer death in Japan. In: Tominaga S, Oshima A, Kuroishi T, Aoki K, (eds) Cancer statistics-1999 (in Japanese). Shinohara Shuppan, Tokyo , pp 171–86
23.
Lozano R, Patt Y, Hassan M, Frome A, Vauthey J, Ellis L et al (2000) Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 19:264a (Abstract No: 1025)
24.
Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C, Glasmacher A (1998) A phase II trial of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 21:232–234CrossRef
25.
Ministry of Health, Labour and Welfare. Statistics and Information Department, Minister’s Secretariat, Ministry of Health, Labour and Welfare. Vital Statistics of Japan 2002 (in Japanese)
26.
Morizane C, Okada S, Okusaka T, Ueno H, Saisho T (2003) Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology 64:475–476CrossRefPubMed
27.
National Cancer Institute (1999) Common Toxicity Criteria (version 2). Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda
28.
Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, et al (2002) Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J cancer 87:702–704CrossRefPubMed
29.
Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K et al (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51:515–517PubMed
30.
Okusaka T (2002) Chemotherapy for biliary tract cancer in Japan. Semin Oncol 29:51–53PubMed
31.
Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K et al (2001) First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 37:1833–1838CrossRefPubMed
32.
Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, et al (2001) Phase II trail of cisplatin, interferon α-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7:3375–3380PubMed
33.
Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM et al (1999) Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22:78–81CrossRefPubMed
34.
Penz M, Kornek GV, Raderer M, Ulroch-Pur H, Fiebiger W, Lenauer A et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186CrossRefPubMed
35.
Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinländer GS, Bareck E, et al (1999) Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary tract cancer. Oncology 56:177–180CrossRefPubMed
36.
Sanz-Altamira PM, Ferrante K, Jenkins R, Lewis WD, Huberman MS, Stuart KE (1998) A phase II trial fo 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82:2321–2325CrossRefPubMed
37.
Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH et al (1993) Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 4:607–609PubMed
38.
Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T et al (2002) Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13:1192–1196CrossRefPubMed
39.
Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T (1994) Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 51:396–400PubMedCrossRef
40.
Valencak J, Kornek GV, Raderer M, Ulrichi-Pur H, Krauss G, Greul R et al (1999) Gemcitabine for the treatment of advanced biliary tract carcinomas: Evaluation of two different dose regimens. Onkologie 22:498–501CrossRef
41.
World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Offset Publication 48. Geneva: World Health Organization
Metadata
Title
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer
Authors
Takuji Okusaka
Hiroshi Ishii
Akihiro Funakoshi
Kenji Yamao
Shinichi Ohkawa
Soh Saito
Hiroshi Saito
Toshio Tsuyuguchi
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0095-3

Other articles of this Issue 5/2006

Cancer Chemotherapy and Pharmacology 5/2006 Go to the issue

Original Article

The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer

Original Article

Thalidomide does not interact with P-glycoprotein

Original Article

Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C

Original Article

Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial

Original Article

Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer

Original Article

Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits